BriaCell Therapeutics Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1610820
Sentiment: neutral
Topics: disclosure, financials
Related Tickers: BCTX
TL;DR
BriaCell Therapeutics filed an 8-K on Nov 1, 2024, with financial updates.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on November 1, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Ansell Capital Corp. until June 13, 2014, is incorporated in British Columbia and operates in the Pharmaceutical Preparations sector. The filing details its business address and phone number.
Why It Matters
This filing provides an update on BriaCell Therapeutics' regulatory disclosures and financial statements, which are crucial for investors to assess the company's current standing and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and disclosures, not indicating any immediate operational or financial distress.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- Ansell Capital Corp. (company) — Former company name
- November 1, 2024 (date) — Date of earliest event reported
- 20140613 (date) — Date of name change
- British Columbia (jurisdiction) — State or other jurisdiction of incorporation or organization
FAQ
What is the primary purpose of this 8-K filing for BriaCell Therapeutics Corp.?
The primary purpose is to report on Regulation FD Disclosure and Financial Statements and Exhibits, as of November 1, 2024.
When was BriaCell Therapeutics Corp. formerly known by another name?
The company was formerly known as Ansell Capital Corp. until June 13, 2014.
In which jurisdiction was BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. was incorporated in British Columbia.
What is the Standard Industrial Classification (SIC) code for BriaCell Therapeutics Corp.?
The SIC code for BriaCell Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.
What is the business address of BriaCell Therapeutics Corp. as listed in the filing?
The business address is Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
Filing Stats: 583 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-11-01 16:05:18
Filing Documents
- form8-k.htm (8-K) — 43KB
- ex99-1.htm (EX-99.1) — 310KB
- ex99-2.htm (EX-99.2) — 306KB
- ex99-1_001.jpg (GRAPHIC) — 17KB
- ex99-1_002.jpg (GRAPHIC) — 11KB
- ex99-1_003.jpg (GRAPHIC) — 3KB
- ex99-1_004.jpg (GRAPHIC) — 2KB
- ex99-2_001.jpg (GRAPHIC) — 14KB
- ex99-2_002.jpg (GRAPHIC) — 6KB
- ex99-2_003.jpg (GRAPHIC) — 12KB
- ex99-2_004.jpg (GRAPHIC) — 13KB
- ex99-2_005.jpg (GRAPHIC) — 19KB
- ex99-2_006.jpg (GRAPHIC) — 14KB
- ex99-2_007.jpg (GRAPHIC) — 12KB
- ex99-2_008.jpg (GRAPHIC) — 15KB
- 0001493152-24-043322.txt ( ) — 1165KB
- bctx-20241101.xsd (EX-101.SCH) — 4KB
- bctx-20241101_def.xml (EX-101.DEF) — 29KB
- bctx-20241101_lab.xml (EX-101.LAB) — 36KB
- bctx-20241101_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams November 1, 2024 William V. Williams President and Chief Executive Officer